- In July 2024, Israeli women’s health company OCON Therapeutics raised US$10 million to expand its health solutions, including painless and effective IUDs and treatment for endometriosis. The company has raised a total of USD 40 million to date, including the most recent round of funding
- In January 2024, Medicines360, a global nonprofit in women's health, and DKT WomanCare, a global distributor of contraceptive products, partnered to expand access to AVIBELA. AVIBELA is a cost-effective, high-quality hormonal IUD with over 99% effectiveness. This collaboration aims to increase awareness, accessibility, and usage of this highly effective contraceptive option
- In November 2023, pharmaceutical giant Bayer announced a development and license agreement with CrossBay Medical to create a single-handed inserter for intrauterine devices. The project involves integrating CrossBay’s CrossGlide technology with Bayer’s hormonal IUD portfolio
- In June 2023, Pregna International Limited, a company specializing in women's reproductive health, received an initial private equity investment of USD 16 million (INR 130 crore) from India Life Sciences Fund III (ILSF III), managed by the private equity firm InvAscent. This investment aims to fuel Pregna's growth and empower them to address the evolving needs of women globally
- In August 2022, Bayer AG received FDA approval for a supplemental new drug application (sNDA) for Mirena IUD, extending its period of use to up to eight years. This approval is intended to ensure that women have access to the contraceptive options needed at various stages of their reproductive life
- In June’2021, Sebela Pharmaceuticals Inc., collaborated with PRA Health Sciences to conduct a phase III clinical trial to assess LevoCept. The product is a long-acting reversible intrauterine system for contraceptive safety, tolerability and efficacy. The trial is going to be completed
